Change over period: —
NSE · PPLPHARMA
PPLPHARMA
-3.0% from the 52-week high · +79.3% above the low
Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 6,295 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 17 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
The short version. PPLPHARMA reported revenue of ₹2,617 crore for Sep 2026, up 28.0% from a year earlier. Net profit was ₹6 crore. Return on equity was -4.0% in Mar 2026. Promoter holding was 34.8% in Sep 2026, down 0.15 points over 8 quarters.
1 · The price
How has the stock traded?
PPLPHARMA trades 3.0% below its 52-week high and 79.3% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹2,617 cr.
5.1 pts higher than a year earlier.
Revenue compounded at 7.5% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2617 | 2270 | 2752 | 2140 | 2044 | 1934 | 2754 | 2204 |
| Net profit | 6 | -69 | -9 | -136 | -99 | -82 | 154 | 4 |
| Net margin % | 0.2 | -3.1 | -0.3 | -6.4 | -4.9 | -4.2 | 5.6 | 0.2 |
| EPS (₹) | 0.04 | -0.52 | -0.07 | -1.02 | -0.75 | -0.61 | 1.16 | 0.03 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 8869 | 9151 | 8171 | 7082 |
| Net profit | -326 | 91 | 18 | -186 |
| Net margin % | -3.7 | 1.0 | 0.2 | -2.6 |
| EPS (₹) | -2.45 | 0.69 | 0.13 | -1.41 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -4.0% in Mar 2026; debt to equity is 0.67.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | -4.0 | 1.1 | 0.2 | -2.8 |
| Return on capital % | 0.8 | 6.4 | 5.2 | 1.6 |
| EBITDA margin % | 10.3 | 17.0 | 15.7 | 11.6 |
| Net margin % | -3.6 | 1.0 | 0.2 | -2.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 7.5% | — |
| Profit CAGR | 20.5% | — |
4 · The owners
Who holds it, and are they adding?
Down 0.15 pts over 8 quarters.
Down 18.03 pts over 8 quarters.
Up 0.34 pts over 8 quarters.
+30 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 34.95 | 34.95 | 34.86 | 34.86 | 34.86 | 34.86 | 34.8 | 34.8 | -0.15 |
| FII | 31.68 | 31.49 | 30.86 | 30.27 | 29.66 | 30.18 | 12.52 | 13.65 | -18.03 |
| DII | 14.1 | 14.78 | 14.26 | 14.89 | 15.69 | 15.61 | 14.57 | 14.44 | +0.34 |
| Public | 18.87 | 18.44 | 19.45 | 19.47 | 19.35 | 19.01 | 37.63 | 36.71 | +17.84 |
Mutual fund holdings · Oct 2026
109 schemes hold this stock
79 the month before.
- Bajaj Finserv Healthcare Fund7.11% of NAV
- LIC MF HEALTHCARE FUND2.97% of NAV
- LIC MF MANUFACTURING FUND2.95% of NAV
- ICICI Prudential Conglomerate Fund2.89% of NAV
- NIPPON INDIA PHARMA FUND2.61% of NAV
- LIC MF SMALL CAP FUND2.58% of NAV
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND2.24% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund2.23% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for PPLPHARMA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about PPLPHARMA
What is the PPLPHARMA share price?
PPLPHARMA (PPLPHARMA) last closed at ₹239.65, up 0.29% on the day. Its 52-week range is ₹133.27 to ₹246.37.
What is the market cap of PPLPHARMA?
PPLPHARMA has a market capitalisation of about ₹31,763 crore.
How are PPLPHARMA's latest results?
PPLPHARMA reported revenue of ₹2,617 crore for Sep 2026, up 28.0% from a year earlier. Net profit was ₹6 crore. Return on equity was -4.0% in Mar 2026. Promoter holding was 34.8% in Sep 2026, down 0.15 points over 8 quarters.
Who owns PPLPHARMA?
As of Sep 2026, shareholding was: Promoter 34.8%, FII 13.65%, DII 14.44%, Public 36.71%.
How many mutual funds hold PPLPHARMA?
109 mutual fund schemes held PPLPHARMA in October 2026. That compares with 79 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 16 Jul 2025 · Final Dividend - Rs. 0.14
- 12 Jul 2024 · Final Dividend - Rs. 0.11
- 02 Aug 2023 · Rights issue 5:46
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.